International Expansion And Pipeline Developments Will Reshape Aesthetics Markets

Published
29 May 25
Updated
15 Aug 25
AnalystConsensusTarget's Fair Value
US$19.00
60.9% undervalued intrinsic discount
15 Aug
US$7.43
Loading
1Y
-53.0%
7D
11.1%

Author's Valuation

US$19.0

60.9% undervalued intrinsic discount

AnalystConsensusTarget Fair Value

Shared on07 Aug 25
Fair value Decreased 19%

Evolus’s valuation outlook is slightly more cautious due to a higher discount rate, while future earnings expectations remain stable, resulting in an unchanged consensus price target of $23.57. What's in the News Evolus updated 2025 earnings guidance, projecting total net revenues between $295–$305 million (11%–15% growth over 2024) and increasing Evolysse injectable HA gels' revenue contribution to 10%–12%.